Secondary Logo

Journal Logo

Institutional members access full text with Ovid®

Fractionated Doses of Oral Etoposide in the Treatment of Patients With AIDS-Related Kaposi Sarcoma

A Clinical and Pharmacologic Study to Improve Therapeutic Index

Sprinz, Eduardo, M.D., Ph.D.; Caldas, Ana P. F., MSc.; Mans, Denis R., Ph.D; Cancela, Anna, Biol.; DiLeone, Luciane, R.N., M.Sc.; Dalla Costa, Teresa, Ph.D.; Schwartsmann, Gilberto, M.D., Ph.D.

American Journal of Clinical Oncology: April 2001 - Volume 24 - Issue 2 - p 177-184

The purpose of this study was to examine the antitumor activity, toxic effects, and plasma pharmacokinetics of fractionated doses of oral etoposide aiming at the achievement of prolonged safe and active plasma drug levels in patients with AIDS–related Kaposi sarcoma (KS). This was designed as a phase II trial in which consecutive patients with progressing AIDS-KS after at least 3 months of active antiretroviral therapy received oral etoposide at the dose of 20 mg/m2 every 8 hours daily for 7 days every 21 days, with the study of its plasma pharmacokinetics. Eligible patients were 18 to 60 years old, with a histopathologically confirmed diagnosis of AIDS-related KS, human immunodeficiency virus–positive test, progressing after at least 3 months of active antiretroviral therapy, World Health Organization (WHO) performance status 0 to 3, New York University staging IIA or greater, no active infection except oral candidiasis, normal bone marrow, liver, and renal function, and who signed an informed consent. Objective tumor responses were evaluated after at least one full treatment course according to a modified WHO criteria, and toxicity was evaluated weekly and graded using the National Cancer Institute–Common Toxicity Criteria (NCI-CTC) criteria. For the pharmacokinetic study, plasma was obtained from patients during the first drug administration immediately before and at various time points thereafter. Etoposide was measured after extraction from plasma by a standard high-performance liquid chromatography. Twenty-one patients were accrued for the study, and 18 of them met the eligibility criteria. They were all men, with median age of 36 years old (range: 25–50 years), median WHO performance status 0 (range: 0–3) median CD4+ count (cells/mm3) 67 (range: 8–443), prior AIDS diagnosis in 10 of 18 cases, NYU staging IIA (1 patient), IIB (1), IIIA (7), IIIB (1), IVA (4), and IVB (4) sites of disease: mucocutaneous only (5), mucocutaneous/lymph nodes (5), mucocutaneous/lung (5) and mucocutaneous/lymph nodes/lung (2); and prior cytotoxic treatment in two patients. Seventy-two percent of cases presented some form of toxic effect (NCI-CTC). Leukopenia was documented in 50% of cases, anemia occurred in 61%, whereas thrombocytopenia was documented in 17% of the patients. The main nonhematologic toxicities were nausea and vomiting in 17% of cases and alopecia in 44%. The overall objective response rate was 83%, with 2 complete remissions documented (11%). The median duration of responses was 12 weeks (range: 3–45 weeks). The median t1//2 of etoposide in plasma was 4.11 hours (range: 1.95–9.64), area under the curve was 13.51 μg/h/ml (range: 7.12–24.42), Cmax was 2.17 μg/ml (1.40–4.41), tmax (1.00–2.00), mean residence time 4.62 hours (range: 3.75–5.20 hours), CIt (total clearance) 3.13 l/m2/h (range: 1.49–5.20 l/m2/h), Vd 13.08 l/m2 (range: 6.23–19.65 l/m2), and the median etoposide plasma concentration time greater than 1 μg/ml was 3.69 hours (range: 1.00–6.80 hours). The use of fractionated oral daily doses of etoposide produced significant antitumor activity with manageable clinical toxicity in the individuals with AIDS-KS included in this trial. This more favorable therapeutic index of etoposide could be due to the achievement of more sustained plasma levels of the drug within safe but active concentrations.

From the Department of Internal Medicine, Faculty of Medicine (E.S., L.D., G.S.) and Faculty of Pharmacy, Federal University of Rio Grande do Sul (UFRGS) (A.P.F.C., T.D.C.), Porto Alegre; South-American Office for Anticancer Drug Development (SOAD) (A.P.F.C., D.R.M., A.C., L.D., G.S.), Porto Alegre; and Department of Oncology, Faculty of Medicine, The Lutheran University (ULBRA) (D.R.M., G.S.), Porto Alegre, Brazil.

Address correspondence and reprint requests to Prof. G. Schwartsmann, Department of Medical Oncology, Federal University of Rio Grande do Sul, Academic Hospital (HCPA), Rua Ramiro Barcelos 2350–3rd Floor, Porto Alegre, RS, Brazil.

© 2001 Lippincott Williams & Wilkins, Inc.